-
公开(公告)号：EP2895505A1
公开(公告)日：2015-07-22
申请号：EP13765701.1
申请日：2013-09-17
发明人： TOLBORG, Jakob Lind , FOSGERAU, Keld , NØRREGARD, Pia , JUST, Rasmus , RIBER, Ditte , HAMPRECHT, Dieter Wolfgang , AUGUSTIN, Robert , THOMAS, Leo , RIST, Wolfgang
IPC分类号： C07K14/605 , A61K38/26
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译： 本发明提供了用于治疗肥胖和过量体重，糖尿病和其他相关代谢紊乱的材料和方法。 特别地，本发明提供了在这些方法中有效的新型胰高血糖素类似物肽。 与人胰高血糖素相比，肽可以通过增加对GLP-1受体的选择性来介导其作用。
-
公开(公告)号：EP3271381A1
公开(公告)日：2018-01-24
申请号：EP16713772.8
申请日：2016-03-17
发明人： JUST, Rasmus , DEMMER, Oliver , GIEHM, Lise , VILLADSEN, Jesper Sloth , MUNCH, Henrik Kofoed , SKARBALIENE, Jolanta , DERYABINA, Maria Alexandrovna , HAMPRECHT, Dieter Wolfgang , MATHIESEN, Jesper Mosolff
IPC分类号： C07K14/575 , C07K14/47
CPC分类号： C07K14/575 , A61K38/00 , C07K14/47
摘要： The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
-
公开(公告)号：EP3057984A1
公开(公告)日：2016-08-24
申请号：EP14795564.5
申请日：2014-10-17
IPC分类号： C07K14/605 , A61K38/26
CPC分类号： C07K14/605 , A61K31/137 , A61K31/155 , A61K31/198 , A61K31/485 , A61K31/7048 , A61K38/26 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译： 本发明提供了用于治疗肥胖和过量体重，糖尿病和其他相关代谢紊乱的材料和方法。 特别地，本发明提供了在这些方法中有效的新型酰化胰高血糖素类似物肽。 与人胰高血糖素相比，肽可以通过增加对GLP-1受体的选择性来介导其作用。
-
-
公开(公告)号：EP3510044A1
公开(公告)日：2019-07-17
申请号：EP17761907.9
申请日：2017-09-11
发明人： MATHIESEN, Jesper Mosolff , GIEHM, Lise , MUNCH, Henrik Kofoed , VILLADSEN, Jesper Skodborg , HAMPRECHT, Dieter Wolfgang , HEIM-RIETHER, Alexander , FOSSATI, Giacomo
IPC分类号： C07K14/575 , A61K38/22 , A61P5/48
-
公开(公告)号：EP3057983A2
公开(公告)日：2016-08-24
申请号：EP14793463.2
申请日：2014-10-17
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K38/00
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译： 本发明提供了用于治疗肥胖和过量体重，糖尿病和其他相关代谢紊乱的材料和方法。 特别地，本发明提供了在这些方法中有效的新型胰高血糖素类似物肽。 与人胰高血糖素相比，肽可以通过增加对GLP-1受体的选择性来介导其作用。
-
公开(公告)号：EP2793931A2
公开(公告)日：2014-10-29
申请号：EP12816470.4
申请日：2012-12-19
IPC分类号： A61K38/26 , C07K14/605
CPC分类号： C07K14/605 , A61K38/00 , A61K38/26 , A61K45/06 , A61K2300/00
摘要： The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译： 本发明提供胰高血糖素类似物肽及其用于促进体重减轻或预防体重增加，以及治疗肥胖症或过量体重和相关病症的用途。 该化合物也可用于改善血糖控制和/或治疗糖尿病。 这些化合物尤其可以通过与人胰高血糖素相比增加对GLP-1受体的选择性而介导其作用。
-
公开(公告)号：EP2895505B1
公开(公告)日：2019-11-06
申请号：EP13765701.1
申请日：2013-09-17
发明人： TOLBORG, Jakob Lind , FOSGERAU, Keld , NØRREGARD, Pia , JUST, Rasmus , RIBER, Ditte , HAMPRECHT, Dieter Wolfgang , AUGUSTIN, Robert , THOMAS, Leo , RIST, Wolfgang
IPC分类号： C07K14/605 , A61K38/26
-
公开(公告)号：EP3057984B1
公开(公告)日：2018-07-11
申请号：EP14795564.5
申请日：2014-10-17
IPC分类号： C07K14/605 , A61K38/26 , A61K38/28 , A61K45/06 , A61K31/137 , A61K31/155 , A61K31/198 , A61K31/485 , A61K31/7048
CPC分类号： C07K14/605 , A61K31/137 , A61K31/155 , A61K31/198 , A61K31/485 , A61K31/7048 , A61K38/26 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
-
公开(公告)号：EP3283507A1
公开(公告)日：2018-02-21
申请号：EP16717132.1
申请日：2016-04-15
IPC分类号： C07K14/605 , A61K38/26
摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.015 秒)
